Lifecore Biomedical Announces Changes to Board Membership
Lifecore Biomedical, Inc. (NASDAQ: LFCR), which focuses on pharmaceutical preparations, has revealed some significant changes to its board of directors, along with details about the upcoming annual stockholders meeting. Recent regulatory filings indicate that two key board members will be departing.
Notable Departures from the Board
Jeffrey L. Edwards, currently a director, has decided not to pursue re-election at the upcoming annual meeting. Along with him, Ray Diradoorian has also announced his resignation ahead of the annual gathering. It’s worth noting that these departures are not linked to any conflicts concerning the company’s operations or policies.
Details of the Annual Meeting
The board has set the date for the annual stockholders meeting for November 7, 2024. Additional information about the meeting, such as proposals and the record date, will be detailed in Lifecore Biomedical’s Definitive Proxy Statement on Schedule 14A, which will be filed with the SEC.
Important Deadlines for Shareholders
As this upcoming annual meeting is more than 30 days after last year’s meeting, Lifecore has updated the deadlines for shareholder proposals and nominations. Shareholders wishing to submit valid proposals must do so by October 3, 2024. These submissions must adhere strictly to SEC regulations, Lifecore's Amended and Restated Bylaws, and Delaware state laws.
Nasdaq Compliance Achieved
Lifecore Biomedical recently achieved compliance with Nasdaq’s listing requirements after filing overdue financial reports and holding its annual meeting. As a result, Nasdaq has halted any delisting procedures for Lifecore's common stock. However, the company will remain under close scrutiny until September 4, 2025, to ensure ongoing compliance.
Impressive Revenue Performance
The company also shared impressive results for fiscal 2024, reporting revenues of around $128.3 million, which reflects a 24.2% increase from the previous fiscal year. Nevertheless, for fiscal 2025, Lifecore anticipates sluggish revenue growth due to the current drop in customer inventories and the absence of new product releases.
Appointment of New CFO
In a strategic decision, Ryan Lake has been named the new CFO, taking over from John Morberg. Ryan brings considerable experience from the contract development and manufacturing organization (CDMO) sector, which will help shape future financial strategies for the company.
Outlook for Future Revenue
Looking ahead, Lifecore Biomedical is optimistic about future revenue growth and better profit margins. They project that adjusted EBITDA for fiscal 2025 will fall between $19 million and $21 million. The company plans to enhance its capabilities in viscous and hard-to-handle programs, utilizing advanced isolator filler technologies for development.
Frequently Asked Questions
What board changes has Lifecore Biomedical announced?
Lifecore Biomedical announced that board members Jeffrey L. Edwards and Ray Diradoorian are stepping down, and their decisions are unrelated to any internal issues.
When is the annual meeting for Lifecore Biomedical?
The annual meeting for stockholders is set for November 7, 2024.
What revenue growth did Lifecore Biomedical achieve recently?
Lifecore Biomedical reported a 24.2% increase in revenues for 2024, amounting to $128.3 million compared to the previous year.
Who has been appointed as the new CFO of Lifecore Biomedical?
Ryan Lake has been appointed as Lifecore Biomedical's new CFO, bringing a wealth of experience from the CDMO sector.
What are Lifecore Biomedical's future revenue growth expectations?
The company expects adjusted EBITDA for fiscal 2025 to be between $19 million and $21 million, aiming for improved revenue growth.
